Controlling RECK miR21 Promotes Tumor Cell Invasion and Is Related to Biochemical Recurrence in Prostate Cancer

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorLEITE, Katia R. M.
dc.contributor.authorREIS, Sabrina T.
dc.contributor.authorVIANA, Nayara
dc.contributor.authorMORAIS, Denis R.
dc.contributor.authorMOURA, Caio M.
dc.contributor.authorSILVA, Iran A.
dc.contributor.authorPONTES JR., Jose
dc.contributor.authorKATZ, Betina
dc.contributor.authorSROUGI, Miguel
dc.date.accessioned2015-08-14T15:34:14Z
dc.date.available2015-08-14T15:34:14Z
dc.date.issued2015
dc.description.abstractThe search for biomarkers to characterize prostate cancer aggressiveness has been the objective for the majority of researchers involved with the most prevalent tumor in men. MiRNAs are important for the control of many cellular functions and their deregulation is involved with tumor development and progression. To find miRNAs differentially expressed in prostate cancer and their relation to prognostic factors and biochemical recurrence we studied 53 surgical specimens from men who underwent radical prostatectomy, through a microarray analysis using the microarray platform (GeneChip (R) miRNA Array - Affymetrix) with more than 46,000 probes and 847 mature human miRNAs and transcripts. We defined different as an expression level greater or less than 1.1 with p<0.05. The validation study using qRT-PCR had confirmed miR21 as overexpressed in tumor that have recurred with a risk of 2.5. Transfection of miR-21 using lipid based assay in DU145 cell line, showed decrease in expression of RECK resulting in increase in expression of MMP9. Invasion assay with Matrigel showed increase in tumor cell invasion after miR-21 transfection. We conclude that miR-21 overexpression is related to increased biochemical recurrence after surgical treatment of prostate cancer. And the negative control of RECK results in overexpression of MMP9 promotes increasing tumor cell invasion supporting miR-21 as an oncomiR related to aggressiveness in prostate cancer.
dc.description.indexPubMed
dc.description.sponsorshipCNPq [473540/2010-0]
dc.identifier.citationJOURNAL OF CANCER, v.6, n.3, p.292-301, 2015
dc.identifier.doi10.7150/jca.11038
dc.identifier.issn1837-9664
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/9650
dc.language.isoeng
dc.publisherIVYSPRING INT PUBL
dc.relation.ispartofJournal of Cancer
dc.rightsopenAccess
dc.rights.holderCopyright IVYSPRING INT PUBL
dc.subjectProstate cancer
dc.subjectMicro RNA
dc.subjectMicroarray
dc.subjectBiochemical recurrence
dc.subjectPrognosis
dc.subjectmiR-21
dc.subjectCell invasion
dc.subjectRECK
dc.subjectDU145
dc.subject.othermicrorna expression
dc.subject.otherhepatocellular-carcinoma
dc.subject.otherradical prostatectomy
dc.subject.othermir-21
dc.subject.othermigration
dc.subject.otherdisease
dc.subject.wosOncology
dc.titleControlling RECK miR21 Promotes Tumor Cell Invasion and Is Related to Biochemical Recurrence in Prostate Cancer
dc.typearticle
dc.type.categoryoriginal article
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.citation.scopus46
hcfmusp.contributor.author-fmusphcKATIA RAMOS MOREIRA LEITE
hcfmusp.contributor.author-fmusphcSABRINA THALITA DOS REIS FARIA
hcfmusp.contributor.author-fmusphcNAYARA IZABEL VIANA MOURA
hcfmusp.contributor.author-fmusphcDENIS REIS MORAIS
hcfmusp.contributor.author-fmusphcCAIO MARTINS MOURA
hcfmusp.contributor.author-fmusphcIRAN AMORIM DA SILVA
hcfmusp.contributor.author-fmusphcJOSE PONTES JUNIOR
hcfmusp.contributor.author-fmusphcBETINA STIFELMAN KATZ
hcfmusp.contributor.author-fmusphcMIGUEL SROUGI
hcfmusp.description.beginpage292
hcfmusp.description.endpage301
hcfmusp.description.issue3
hcfmusp.description.volume6
hcfmusp.origemWOS
hcfmusp.origem.pubmed25663948
hcfmusp.origem.scopus2-s2.0-84923686674
hcfmusp.origem.wosWOS:000352138200012
hcfmusp.publisher.cityLAKE HAVEN
hcfmusp.publisher.countryAUSTRALIA
hcfmusp.relation.referenceAlgarra R, 2014, ACTAS UROLOGICAS ESP
hcfmusp.relation.referenceChen Y, 2012, ANTICANCER RES, V32, P2991
hcfmusp.relation.referenceEpstein JI, 2005, AM J SURG PATHOL, V29, P1228, DOI 10.1097/01.pas.0000173646.99337.b1
hcfmusp.relation.referenceEpstein JI, 2012, EUR UROL, V61, P1019, DOI 10.1016/j.eururo.2012.01.050
hcfmusp.relation.referenceHaffner MC, 2013, J CLIN INVEST, V123, P4918, DOI 10.1172/JCI70354
hcfmusp.relation.referenceHaffner MC, 2014, J CLIN ONCOLOGY OFFI
hcfmusp.relation.referenceIrizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249
hcfmusp.relation.referenceKattan MW, 1999, J CLIN ONCOL, V17, P1499
hcfmusp.relation.referenceKollmeier Marisa A, 2012, Crit Rev Oncol Hematol, V84 Suppl 1, pe6, DOI 10.1016/j.critrevonc.2012.12.002
hcfmusp.relation.referenceLeite KRM, 2011, J UROLOGY, V185, P1118, DOI 10.1016/j.juro.2010.10.035
hcfmusp.relation.referenceLeite KRM, 2011, UROL ONCOL-SEMIN ORI, V29, P265, DOI 10.1016/j.urolonc.2009.02.002
hcfmusp.relation.referenceLexander H, 2005, PROTEOMICS, V5, P2570, DOI 10.1002/pmic.200401170
hcfmusp.relation.referenceLi T, 2012, J UROLOGY, V187, P1466, DOI 10.1016/j.juro.2011.11.082
hcfmusp.relation.referenceLu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
hcfmusp.relation.referenceLucca I, 2014, UROLOGIC ONCOLOGY
hcfmusp.relation.referenceMaugeri-Sacca M, 2012, CANCER J, V18, P253, DOI 10.1097/PPO.0b013e318258b5b6
hcfmusp.relation.referenceMoreira Leite Katia Ramos, 2009, Int J Radiat Oncol Biol Phys, V73, P353, DOI 10.1016/j.ijrobp.2008.04.039
hcfmusp.relation.referenceNair VS, 2012, J NATL CANCER I, V104, P528, DOI 10.1093/jnci/djs027
hcfmusp.relation.referenceOsman A, 2012, CLIN LAB, V58, P393
hcfmusp.relation.referenceOzen M, 2008, ONCOGENE, V27, P1788, DOI 10.1038/sj.onc.1210809
hcfmusp.relation.referencePorkka KP, 2007, CANCER RES, V67, P6130, DOI 10.1158/0008-5472.CAN-07-0533
hcfmusp.relation.referenceReis ST, 2012, BMC UROL, V12, DOI 10.1186/1471-2490-12-14
hcfmusp.relation.referenceRibas J, 2009, CANCER RES, V69, P7165, DOI 10.1158/0008-5472.CAN-09-1448
hcfmusp.relation.referenceSchaefer A, 2010, INT J CANCER, V126, P1166, DOI 10.1002/ijc.24827
hcfmusp.relation.referenceTong AW, 2009, CANCER GENE THER, V16, P206, DOI 10.1038/cgt.2008.77
hcfmusp.relation.referenceVolinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103
hcfmusp.relation.referenceWatahiki A, 2013, INT J MOL SCI, V14, P7757, DOI 10.3390/ijms14047757
hcfmusp.relation.referenceZhang BH, 2007, DEV BIOL, V302, P1, DOI 10.1016/j.ydbio.2006.08.028
hcfmusp.relation.referenceZhang HL, 2011, PROSTATE, V71, P326, DOI 10.1002/pros.21246
hcfmusp.relation.referenceZhou L, 2013, INT J ONCOL, V43, P661, DOI 10.3892/ijo.2013.1965
hcfmusp.relation.referenceZhu Q, 2012, ONCOL REP, V27, P1660, DOI 10.3892/or.2012.1682
hcfmusp.scopus.lastupdate2024-05-10
relation.isAuthorOfPublication23772d3b-0da7-472f-8d56-e6312dbf95c1
relation.isAuthorOfPublication73be4bca-f8ad-443f-90b5-10e2e62b1e27
relation.isAuthorOfPublication32f63bee-3f86-4e8d-b307-f29f080dd7b4
relation.isAuthorOfPublication7af4bd17-a1d2-4c42-a4af-e0919576a464
relation.isAuthorOfPublicationbc28b381-6994-4655-9f48-9bc7136e4db9
relation.isAuthorOfPublicationb276e0c0-431e-426d-879c-06108f4cc785
relation.isAuthorOfPublication8f302d44-7ff3-4af9-bb58-76bce498a3a6
relation.isAuthorOfPublication01d7a5da-3983-420d-b86f-291cd9d6378b
relation.isAuthorOfPublicationcff561dd-5732-4af5-abe9-538da0cdf4d2
relation.isAuthorOfPublication.latestForDiscovery23772d3b-0da7-472f-8d56-e6312dbf95c1
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
art_LEITE_Controlling_RECK_miR21_Promotes_Tumor_Cell_Invasion_and_2015.PDF
Tamanho:
490.02 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MCG
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/55
Artigos e Materiais de Revistas Científicas - ODS/03